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Efﬁcacy and Safety of Edoxaban in Elderly Patients With Atrial
Fibrillation in the ENGAGE AF–TIMI 48 Trial
Eri Toda Kato, MD, PhD; Robert P. Giugliano, MD, SM; Christian T. Ruff, MD, MPH; Yukihiro Koretsune, MD, PhD; Takeshi Yamashita, MD,
PhD; Robert Gabor Kiss, MD, PhD; Francesco Nordio, PhD; Sabina A. Murphy, MPH; Tetsuya Kimura, MS; James Jin, PhD; Hans Lanz, MD;
Michele Mercuri, MD, PhD; Eugene Braunwald, MD; Elliott M. Antman, MD
Background-—Elderly patients with atrial ﬁbrillation are at higher risk of both ischemic and bleeding events compared to younger
patients. In a prespeciﬁed analysis from the ENGAGE AF-TIMI 48 trial, we evaluate clinical outcomes with edoxaban versus warfarin
according to age.
Methods and Results-—Twenty-one thousand one-hundred and ﬁve patients enrolled in the ENGAGE AF-TIMI 48 trial were
stratiﬁed into 3 prespeciﬁed age groups: <65 (n=5497), 65 to 74 (n=7134), and ≥75 (n=8474) years. Older patients were more
likely to be female, with lower body weight and reduced creatinine clearance, leading to higher rates of edoxaban dose reduction
(10%, 18%, and 41% for the 3 age groups, P<0.001). Stroke or systemic embolic event (1.1%, 1.8%, and 2.3%) and major bleeding
(1.8%, 3.3%, and 4.8%) rates with warfarin increased across age groups (Ptrend<0.001 for both). There were no interactions between
age group and randomized treatment in the primary efﬁcacy and safety outcomes. In the elderly (≥75 years), the rates of stroke/
systemic embolic event were similar with edoxaban versus warfarin (hazard ratio 0.83 [0.66–1.04]), while major bleeding was
signiﬁcantly reduced with edoxaban (hazard ratio 0.83 [0.70–0.99]). The absolute risk difference in major bleeding (82 events/
10 000 pt-yrs) and in intracranial hemorrhage (73 events/10 000 pt-yrs) both favored edoxaban over warfarin in older patients.
Conclusions-—Age has a greater inﬂuence on major bleeding than thromboembolic risk in patients with atrial ﬁbrillation. Given the
higher rates of bleeding and death with increasing age, treatment of elderly patients with edoxaban provides an even greater
absolute reduction in safety events over warfarin, compared to treatment with edoxaban versus warfarin in younger patients.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identiﬁer: NCT00781391. ( J Am Heart Assoc. 2016;5:
e003432 doi: 10.1161/JAHA.116.003432)
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A trial ﬁbrillation (AF) is the most common arrhythmiaencountered in clinical practice, and its prevalence is
strongly related to age,1–4 predisposing the elderly to an
increased risk of embolic stroke. Although oral anticoagulant
therapy with vitamin K antagonists effectively reduces the risk
of ischemic stroke in patients with AF,5 there is a known
increased bleeding risk with vitamin K antagonists, particu-
larly in the elderly.6–8 Thus, older age is an overlapping factor
in both the CHA2DS2-VASc score for stroke,
9 and the HAS-
BLED score for bleeding risk,10 and frequent international
normalized ratio monitoring is recommended to ensure the
optimal level of anticoagulation with vitamin K antagonists in
the elderly. In addition, the use of vitamin K antagonists is
limited by multiple drug and food interactions. As a conse-
quence, anticoagulants are underused in the elderly, despite
their high risk of ischemic events.11,12
Edoxaban, a direct oral factor Xa inhibitor, has a linear
pharmacokinetic proﬁle and is given once daily. In the Effective
aNticoaGulation with factor Xa next GEneration in Atrial
Fibrillation–Thrombolysis In Myocardial Infarction study 48
(ENGAGE AF–TIMI 48), 2 dose regimens of edoxaban were
noninferior to well-managed warfarin in preventing stroke or
systemic embolic events (SEE) while reducing major bleeding
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and death from cardiovascular causes in patients with AF.
Likewise, other non–vitamin K oral anticoagulants (NOACs) have
proven to be at least as effective as warfarin in reducing stroke
with lower major bleeding rates.13 However, subgroup analyses
from 2 of these newer agents, namely, dabigatran and rivarox-
aban, as compared to warfarin, have demonstrated a reduced
safety margin with respect to bleeding in the elderly.14,15
As previously reported in a pharmacokinetic and outcomes
analysis, the risk of stroke or SEE with edoxaban decreases
gradually and linearly with increasing edoxaban concentration,
in contrast with the steeper increase in the risk of major
bleeding.16 Thus, the therapeutic window for edoxaban is
narrower for major bleeding than thromboembolism.
Given the concern over increased risk of bleeding in the
elderly, we evaluated the efﬁcacy and safety of edoxaban
compared with warfarin stratiﬁed by age in the ENGAGE AF-
TIMI 48 trial.
Methods
Study Design and Study Population
The design and results of ENGAGE AF-TIMI 48 have been
described previously.17,18 In brief, ENGAGE AF-TIMI 48 was a
randomized, double-blind, double-dummy trial to establish the
noninferiority of edoxaban compared with warfarin. Twenty-one
thousand one-hundred and ﬁve patients with moderate-to-high-
risk AF were randomized with a median follow-up of 2.8 years.
The protocol and amendmentswere approved by all institutional
review committees and all patients provided written informed
consent. Edoxaban was provided by the sponsor, Daiichi-
Sankyo (Edison, NJ), who also funded the trial. Eligible patients
were 21 years of age or older with documented AF within the
12 months preceding randomization at medium or high risk of
thromboembolic events (CHADS2 risk score ≥2).
19 Key exclu-
sion criteria were an estimated creatinine clearance (CrCl)
<30 mL/min; a condition associatedwith a high risk of bleeding
(eg, prior intracranial hemorrhage [ICH], gastrointestinal bleed-
ing or active peptic ulcer in the prior year, major surgery or
trauma in the preceding 10 days, uncontrolled hypertension,
hemorrhagic disorder); moderate to severe mitral stenosis or
mechanical heart valve, need for dual antiplatelet therapy, and
an acute coronary syndrome, stroke, or revascularization
procedure within 30 days prior to enrollment.17,18 There was
no upper age limit for participation. Patientswere seen in follow-
up atmonths 1, 3, and every 3 months thereafter, at which time
a complete blood count and creatinine were measured.
Randomization and Study Drugs
Patients were randomized in a 1:1:1 ratio to a higher-dose
edoxaban regimen (HDER) (60 mg once daily), a lower-dose
edoxaban regimen (LDER) (30 mg once daily), or to warfarin
titrated to achieve a target international normalized ratio of
2.0 to 3.0. The dose of edoxaban was reduced by 50% if any
of the following characteristics were present at the time of
randomization or during the study: calculated CrCl of
≤50 mL/min using the Cockcroft-Gault formula,20 body
weight of 60 kg or less, or the concomitant use of potent
P-glycoprotein inhibitors.
Edoxaban Concentration
Plasma concentration and anti-Factor Xa (FXa) activity were
assessed using previously described methods16 and were
analyzed by age group. Trough blood samples were collected
1 month after randomization. Plasma concentrations of
edoxaban were measured by Quintiles Bioanalytical and
ADME Laboratories using a validated turbo ion spray liquid
chromatography mass spectrometry (LC-MS)/MS method.
Anti-factor Xa activity was measured by the Rotachrome
Heparin assay on the Stago STAR Evolution platform (TIMI
Clinical Trials Laboratory, Boston, MA).16
Study End Points
The primary efﬁcacy end point was a composite of all stroke or
SEE. Key secondary end points included the net clinical end
point of stroke, SEE,major bleeding, or death fromany cause, as
well as each of these end points individually. The principal safety
end point was major bleeding as deﬁned by the International
Society on Thrombosis and Haemostasis.21 All primary and
secondary end points were adjudicated by independent blinded
central event adjudication committee members.
Statistical Analysis
The data were analyzed by prespeciﬁed age categories (<65,
65–74, and ≥75 years) and the elderly were deﬁned as
patients ≥75 years of age. We hypothesized that the efﬁcacy
and safety proﬁle of edoxaban relative to warfarin would be
consistent across age groups. Baseline characteristics were
reported as frequencies and percentages for categorical
variables and as medians and interquartile ranges for
continuous variables. Baseline characteristics were compared
using the v2 test for categorical, and Wilcoxon rank sum test
for continuous variables.
Outcomeswere presented as the total number of ﬁrst events
and annualized event rates, and were examined by Cox
proportional hazard models. Multivariate regression models
were used to adjust for differences (univariate P<0.05) in
baseline characteristics across age groups. Each of the
continuous variables were tested for linearity before being
included in the model, and as such, creatinine was included as
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restricted cubic spline with 4 knots to account for nonlinearity.
The variables included in the model were the following: sex,
body mass index, creatinine, hypertension, dyslipidemia, dia-
betes, smoking, prior stroke or transient ischemic attack, heart
failure, type of AF, race, region, increased risk of falling, risk of
neuropsychiatric disease, coronary artery disease, history of
hepatic disease, history of extracranial hemorrhage, alcohol
intake, and medication predisposing to bleeding.
The impact of age on outcomes was ﬁrst evaluated
exclusively in the warfarin group to eliminate the inﬂuence of
a possible difference in age-related treatment response.
Interactions between the randomized treatment and the age
categories were then tested by Cox proportional hazard
modeling to address effect modiﬁcation by age group. Differ-
ences between randomized treatment groups are presented
both as hazard ratios (HR) and absolute risk differences (ARD)
since event rates varied widely across age groups.
Additionally, primary end points were analyzed by age as a
continuous variable using restricted cubic splines to evaluate
for nonlinear relationships between age and outcomes and to
conﬁrm the prespeciﬁed age cut points. Furthermore, in
exploratory analyses, efﬁcacy and safety were evaluated in
several post-hoc subgroups (i.e., the very elderly populations
[≥80 and ≥85 years]) and those meeting criteria for dose
reduction.
All analyses were performed using the SAS software,
version 9.3 (SAS Institute Inc., Cary, NC). A 2-sided P<0.05
was considered to indicate statistical signiﬁcance, without
adjustment for multiple comparisons.
Due to a higher rate of ischemic stroke with LDER as
compared to warfarin, LDER was not submitted for regulatory
reviews. Only the HDER regimen has been approved by
regulatory authorities around the world for stroke prevention
in patients with AF. However, we also describe detailed
results with LDER in the Supplement (Table S2b, Figures S2
and S3), given the higher risk of bleeding in the elderly and
since there is strong clinical interest in understanding how the
risk–beneﬁt of lower intensity anticoagulation compares to
warfarin in this more vulnerable subgroup.
Results
Patient Characteristics
Of the 21 105 patients randomized in the ENGAGE AF-TIMI
48, the median age was 72 years (interquartile range, 64–78),
and 8474 (40.2%) were ≥75 years (Figure S1). Characteristics
of patients according to age category are summarized in
Table. The elderly were more likely to be female, had lower
CrCl and body weight, and thus were more likely to meet
criteria for an edoxaban dose reduction at baseline (41% in
the elderly as compared to 10% and 18% in the other 2 age
groups, P<0.001). The median time in therapeutic range with
warfarin was higher in the elderly compared with the younger
(67.2%, 68.4%, and 69.6%, for <65, 65–74, and ≥75 years,
respectively, Ptrend<0.001). Baseline characteristics within
each age category were similar by randomized treatment
group (P>0.05 for all).
Outcomes by Age in the Warfarin Group
The annualized rates of major efﬁcacy and safety outcomes in
the warfarin group increased signiﬁcantly with age, but
particularly for bleeding events. After adjustment for baseline
differences, older age remained an independent risk factor for
adverse outcomes. In the elderly, there were 2-fold increases in
stroke or SEE, and in ischemic stroke, a 3-fold increase in
International Society on Thrombosis and Haemostasis major
bleeding and a 4-fold increase in ICH compared to the youngest
age group (Ptrend≤0.001 for each end point, Figure 1).
When age was analyzed as a continuous variable, the
probabilities of major bleeding exceeded that of stroke or SEE
with warfarin across the range of age (Figure 2). Both risks
increased as age increased, with a visually prominent increase
in age ≥75 years, and with an even steeper slope for major
bleeding (Figure 2).
Outcomes by Treatment and Age
There was no signiﬁcant effect modiﬁcation by age group on
the relative treatment effect of HDER as compared to warfarin
for the primary and key secondary efﬁcacy, safety, and net
clinical outcome analyses (Pinteraction>0.05 for each compar-
ison, Figure 3).
In the comparison of HDER with warfarin in elderly
patients, the HRs and ARDs were the following: HR: 0.83
(0.66–1.04), ARD: 40 events/10 000 pt-yrs for stroke or
SEE, HR: 0.83 (0.70–0.99), ARD: 82 events/10 000 pt-yrs
for major bleeding, and HR: 0.40 (0.26–0.62), ARD:
73 events/10 000 pt-yrs for ICH. The primary net clinical
outcome in the elderly was improved (HR: 0.88 [0.79–0.97],
ARD: 144/10 000 pt-yrs), as were the secondary and
tertiary net outcomes (Figure 4). Since event rates for
thromboembolic events, bleeding, and death were higher in
the elderly, the absolute numeric reductions in these events
when edoxaban was compared to warfarin were more marked
in older patients. Corresponding results with the LDER versus
warfarin are shown in Figures S2 and S3.
Special Subgroups
Dose reduction
Overall, there were 5356 (25.4%) patients who met criteria for
dose reduction (10.4%, 18.2%, and 41.2% of patients age <65,
DOI: 10.1161/JAHA.116.003432 Journal of the American Heart Association 3
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65–74, and ≥75 years, respectively). Among the 3488 elderly
patients whomet dose reduction criteria, 2960 (84.9%) patients
were dose-reduced due to moderate renal dysfunction (CrCl
30–50 mL/min at screening visit). Regardless of dosage, the
edoxaban concentration and anti-FXa activity were similar
across age groups with broad overlap in dose groups (Table S1).
Table. Patient Characteristics by Age Group
Characteristics
<65 y
(N=5497, 26.0%)
65 to 74 y
(N=7134, 33.8%)
≥75 y
(N=8474, 40.2%)
Age, y 59 [55.0–62.0] 70 [67.0–72.0] 79 [76.0–82.0]
Weight, kg 91.0 [77.6–106.0] 83.0 [71.0–95.7] 76.0 [65.9–86.5]
Female sex 1510 (28) 2753 (39) 3777 (45)
Hypertension 5166 (94) 6731 (94) 7857 (93)
Dyslipidemia 2803 (51) 3836 (54) 4419 (52)
Diabetes 2235 (41) 3053 (43) 2336 (28)
Current smoking 738 (13) 490 (6.9) 324 (3.8)
Prior PCI 286 (5.2) 500 (7.0) 654 (7.7)
Prior stroke or TIA 1520 (28) 2334 (33) 2119 (25)
Congestive heart failure 3832 (70) 4477 (63) 3815 (45)
Type of AF
Paroxysmal 1405 (26) 1789 (25) 2172 (26)
Persisent 1349 (25) 1636 (23) 1883 (22)
Permanent 2741 (50) 3709 (52) 4415 (52)
CrCl (mL/min) at randomization 98 [79–123] 74 [60–90] 56 [45–69]
≤50 145 (2.6) 813 (11) 3116 (37)
>50 to 80 1280 (23) 3504 (49) 4381 (52)
>80 4072 (74) 2817 (40) 977 (12)
Race
White 4304 (78) 5719 (80) 7044 (83)
Asian 872 (16) 1048 (15) 989 (12)
Black 113 (2.1) 95 (1.3) 70 (0.8)
Other 208 (3.8) 272 (3.8) 370 (4.4)
CHADS2 score
Mean (SD) 2.6 (0.8) 2.7 (0.8) 3.2 (1.1)
4 to 6 821 (15) 1203 (17) 2744 (32)
CHA2DS2-VASc score
Mean (SD) 3.2 (1.1) 4.4 (1.1) 5.0 (1.3)
4 to 9 1815 (33) 5626 (79) 7478 (88)
HAS-BLED score ≥3 894 (16) 4129 (58) 4779 (56)
Time in therapeutic range 67.2 [55.5–75.9] 68.4 [57.1–77.4] 69.6 [57.1–78.3]
Dose reduction at randomization 571 (10) 1297 (18) 3488 (41)
Prior VKA experience 2978 (54) 4285 (60) 5178 (61)
Medication at time of randomization
Aspirin 1647 (30) 2073 (29) 2460 (29)
Thienopyridine 113 (2.1) 169 (2.4) 205 (2.4)
Data shown are number (%) unless otherwise indicated. Data presented are median (interquartile ranges) for continuous variables and number (percentages) for categorical variables. Race
was self-reported. AF indicates atrial ﬁbrillation; CrCl, creatinine clearance; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; VKA, vitamin K antagonists.
Ptrend<0.001 for all comparisons except for dyslipidemia (Ptrend=0.33), aspirin use (Ptrend=0.27), and thienopyridine use (Ptrend=0.18).
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Dose reduction resulted in a decrease in median exposure of
30% to 40% in all age groups and a maximum decrease in anti-
FXa activity of 40% in the elderly. Observed event rates for both
stroke or SEE and for major bleeding were generally higher with
increasing age both in patients who did and who did not meet
dose reduction criteria (Tables S2 and S3).
The efﬁcacy and safety proﬁles of edoxaban as compared
to warfarin were consistent regardless of dose reduction and
age group (Pinteraction>0.05), with the exception of major
bleeding in the elderly. Dose reduction from 60 to 30 mg in
elderly patients randomized to the HDER who met 1 of the 3
prespeciﬁed criteria for dose reduction at randomization
decreased major bleeding as compared to warfarin to an even
greater degree, than among elderly patients treated with
HDER who were not dose-reduced (HDER versus warfarin; HR
0.58 [0.43–0.77] for dose reduction, HR 1.06 [0.84–1.33] for
no dose reduction, Pinteraction=0.0013, Table S2). There also
was a similar signiﬁcant interaction observed with LDER
(Pinteraction=0.0001, Table S3).
Three-way interactions between age group, dose reduc-
tion status, and randomized treatment were not statistically
signiﬁcant when HDER was compared with warfarin with
regard to primary efﬁcacy end point (Pinteraction=0.52) and
primary safety end point (Pinteraction=0.09). Similarly, the 3-
way interaction was not signiﬁcant for primary efﬁcacy end
point with LDER (Pinteraction=0.82, Table S3). However, there
was a marginal signiﬁcant interaction with the primary safety
end point (Pinteraction=0.05).
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1.83 (1.32- 2.54) 1.81 (1.24- 2.63) 2.68 (2.04- 3.52) 3.77 (1.94- 7.30)
Adjusted HR (95% CI)
65-74 vs. <65 years;
≥75   vs. <65 years;
Ptrend all<0.01
(N=337) (N=235) (N=524) (N=132)
57 112 168 44 69 122 81 173 270 12 50 70
Figure 1. Inﬂuence of age on outcomes (warfarin group only). Multivariable model included all baseline
characteristics with univariate P<0.05 (body mass index, sex, creatinine, hypertension, dyslipidemia,
diabetes, smoking, prior stroke or transient ischemic attack, heart failure, type of atrial ﬁbrillation, race,
region, increased risk of falling, risk of neuropsychiatric disease, coronary artery disease, history of hepatic
disease, history of nonintracranial hemorrhage, alcohol intake, and medication predisposing to bleeding).
HR indicates hazard ratio.
Figure 2. Calculated probabilities by continuous age. The out-
comes were analyzed by age as a continuous variable for stroke or
SEE (blue line) and major bleeding (red line). The dotted lines
represent the 95% CI. SEE indicates systemic embolic event.
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Post hoc analysis of very elderly groups (age ≥80 and
age ≥85)
We additionally explored the very elderly groups: 3591 (17.0%)
patients aged ≥80 and 899 (4.3%) patients aged ≥85, given the
aging population and increased prevalence of AF with advanced
age. Baseline characteristics for the very elderly groups
≥80 years of age and ≥85 years of age are provided in Tables
S4 and S5, respectively. As shown in Table S6, patients
≥80 years of age had even higher event rates compared to
patients ≥75 years. Comparisons of the efﬁcacy and safety of
edoxaban and warfarin, stratiﬁed at age 80, were similar to
analyses using the 3 prespeciﬁed age cut points, with no
signiﬁcant treatment interactions between age-groups and
treatment for all major outcomes. Similar ﬁndings were
observed in patients ≥85 years of age (Table S7).
Discussion
Of 21 105 subjects enrolled in the ENGAGE AF-TIMI 48 trial,
8474 patients were ≥75 years of age. This represents the
largest number of elderly patients enrolled among the
randomized controlled trials with a NOAC to date. In this
prespeciﬁed analysis, we conﬁrmed the strong relationships
between age and risk of both thromboembolism and bleeding
in patients with AF, even after adjustment for potential
confounders. Notably, however, age had a greater impact on
bleeding. As age increases, the slope for major bleeding
increases more sharply than the corresponding slope for
stroke or SEE, particularly above the age of 75 years. Similar
ﬁndings of a greater inﬂuence of age on bleeding as compared
to thromboembolic events were reported in a randomized trial
of 973 patients age ≥75 years with atrial ﬁbrillation random-
ized to warfarin or aspirin.22
Due to the higher thromboembolic and particularly bleeding
risk in the elderly as compared to the younger patients, the
absolute beneﬁts of edoxaban over warfarin were more
marked in older patients, as compared to the beneﬁts of
edoxaban versus warfarin in younger patients. Importantly,
with edoxaban, the incidence of ICH, the most feared
complication of anticoagulant therapy, increased only gradu-
ally with increasing age, in contrast to a steeper increase in
Figure 3. Efﬁcacy and safety outcomes comparing the higher-dose edoxaban regimen
vs warfarin by age. Intracranial hemorrhage (ICH) and major bleeding events include
primary ischemic strokes with hemorrhagic conversion. GI indicates gastrointestinal; HR
indicates hazard ratio; SEE, systemic embolic event.
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ICH rates with warfarin as age increases. As a result, there was
a more pronounced relative decline in International Society on
Thrombosis and Haemostasis major bleeding with edoxaban
as compared to warfarin as age increased; this was particularly
apparent among the elderly who met dose reduction criteria at
randomization. Furthermore, edoxaban provided superior
absolute net clinical outcomes over warfarin in the elderly,
including the secondary and tertiary net clinical outcomes,
which were limited to more serious irreversible outcomes.
Although comparisons across the warfarin-controlled trials
of NOACs are challenging due to differences in trial entry
criteria, the frequency and degree of dose reduction of NOAC,
and deﬁnitions of bleeding, qualitative comparisons of results
help put our results into a contemporary context. There were
no interactions between treatment effect and age for the
primary efﬁcacy and safety end points in ENGAGE AF-TIMI 48.
This is in contrast with the results from RE-LY14 and ROCKET
AF15 in which there were statistically signiﬁcant treatment
interactions with age with respect to bleeding outcomes14,15;
bleeding rates in the elderly with dabigatran and with
rivaroxaban were numerically greater than with warfarin.
Our results are most consistent with those with apixaban in
the ARISTOTLE trial,23 in which there was no signiﬁcant effect
modiﬁcation of NOAC treatment by age. In ENGAGE AF-TIMI
48 and ARISTOTLE trials, the absolute major bleeding rates
were consistently lower with the NOAC than with warfarin
across all age groups.
In addition, we found no signiﬁcant treatment interactions
with age with respect to various primary and secondary safety
end points including International Society on Thrombosis and
Haemostasis major bleeding, ICH, fatal bleeding, major
gastrointestinal bleeding, and minor bleeding with the HDER.
Directionally opposite signiﬁcant interactions were reported in
the primary safety events of RE-LY and ROCKET AF.14,15 It is
noteworthy that dose reduction in the elderly was most
frequent in ENGAGE AF-TIMI 48, and the reduction in dose of
50% was greater than in the ROCKET-AF (25%) and RE-LY (no
dose reduction) trials.
We further explored subgroups of patients aged ≥80 and
≥85 years (Tables S6 and S7), and additionally performed
sensitivity analyses using the same cut points as ROCKET AF
(<75 and ≥75 years) (Table S8). The treatment effects were
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Figure 4. Absolute risk differences in net clinical outcomes with the higher-dose edoxaban regimen as
compared to warfarin. Primary Net Clinical Outcome: stroke, systemic embolic events, major bleeding, or
death from any cause. Secondary Net Clinical Outcome: disabling stroke, life-threatening bleeding, or
death from any cause. Tertiary Net Clinical Outcome: stroke, systemic embolic events, life-threatening
bleeding, or death from any cause. Higher-dose edoxaban regimen compared to warfarin; primary net
clinical outcome; age <65 years; HR 0.99 (0.82–1.18), 65 to 74 years; 0.87 (0.76–1.00), and ≥75 years;
0.88 (0.79–0.97); Pinteraction=0.48, secondary net clinical outcome age <65 years; HR 1.11 (0.89–1.37),
65 to 74 years; 0.81 (0.69–0.96), and ≥75 years; 0.86 (0.76–0.97); Pinteraction=0.07, tertiary net clinical
outcomes; age <65 years; HR 1.1 (0.85–1.28), 65 to 74 years; 0.83 (0.71–0.97), and ≥75 years; 0.85
(0.76–0.97); Pinteraction=0.16. *P<0.05 for comparison vs warfarin. HDER indicates higher-dose edoxaban
regimen; HR, hazard ratio; Pt-yr, patient years; yr, years.
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comparable in these sensitivity analyses, thereby demon-
strating the robustness of the ﬁndings with edoxaban in the
elderly.
In a pharmacokinetic analysis from the RE-LY trial,24
efﬁcacy and safety outcomes were associated with dabigatran
plasma concentration, in which age and renal function, 2
highly correlated covariates, were the major determining
factors. In ENGAGE AF-TIMI 48, while age itself was not
included as 1 of the criteria for dose reduction, 41% of
patients ≥75 years of age received a dose reduction, most
commonly (89%) due to the presence of moderate renal
dysfunction (CrCl <50 mL/min). As such, edoxaban plasma
concentration and anti-FXa activity increased only slightly
with increasing age.
In the elderly, dose reduction resulted in a decrease in
median edoxaban plasma concentration of 30% to 40% and a
decrease in median anti-FXa activity of 20% to 40%. However,
the efﬁcacy of edoxaban compared with warfarin in preventing
stroke or SEE was preserved, while there was a signiﬁcant
interaction demonstrating an even greater reduction in major
bleeding among elderly who received a dose reduction of
edoxaban as compared to similar patients in the warfarin
group (Pinteraction<0.01). These ﬁndings are consistent with
previous analyses in the overall ENGAGE AF-TIMI 48 popula-
tion, showing that dose reduction did not alter relative
treatment efﬁcacy, but did provide a greater reduction in
major bleeding with edoxaban as compared with warfarin.16,17
As age is a strong predictor of bleeding events, and since
edoxaban has a relatively wider therapeutic window for
thromboembolism than major bleeding,16 our results support
the dose reduction strategy incorporated in the ENGAGE AF-
TIMI 48 trial. These ﬁndings reinforce the importance of
selecting the right dose for patients, particularly in elderly
patients with renal dysfunction, to avoid excess bleeding. The
high frequency of moderate renal insufﬁciency in the elderly
underscores the need for close monitoring of ﬂuctuations in
renal function to ensure proper dosing. A recent practical
guide on the use of NOACs suggests repeat assessment of
renal function at intervals in months equal to the CrCl divided
by 10 for patients with a CrCl <60 mL/min (for example, a
patient with CrCl of 40 mL/min is recommended to have
repeat measurements every 4 months).25
Limitations to the current analysis warrant consideration.
Elderly patients in a clinical trial may be relatively more
healthy and compliant than elderly in a general population. In
fact, the elderly patients in ENGAGE AF-TIMI 48 had a lower
rate of diabetes, and had a higher time in therapeutic range
(69.6%) compared to younger patients. In addition, the trial
included a small proportion of frail elderly or elderly with
neurocognitive dysfunction, since participation in a complex
long-term clinical trial would have been difﬁcult for these
more vulnerable patients. However, more than 30% of the
elderly had a CHADS2 score ≥4, 35% had moderate renal
dysfunction, and event rates with warfarin were similar to
those reported in other NOAC trials. Minority elderly patients
were underrepresented in this trial; hence extrapolation of our
ﬁndings to such subgroups requires caution. In addition, the
prespeciﬁed age cut points were based on CHA2D2S2-VASc
cut points,19 and although nonlinear relationships between
age and primary outcomes were explored, these cut points
may not be optimal for other end points. Also, since the
sample size of the trial was not powered for any of the
subgroup analyses and event rates were relatively low, some
subgroup analyses had very few events and therefore the
power was limited.
Conclusions
Age is a stronger predictor of bleeding events compared to
thromboembolic events in patients with AF. The relative
reduction in major bleeding with edoxaban compared to
warfarin was similar across age groups. However, due to the
higher absolute rates of bleeding with increasing age, an even
greater absolute numeric reduction in the rates of major
bleeding was observed with edoxaban versus warfarin among
elderly patients than was observed with edoxaban versus
warfarin in younger patients.
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Supplementary Table S1. Edoxaban Trough Concentration and Anti-FXa Activity at Trough by Age and 
Dose Reduction 
   <65 year 65-74 year ≥75 year 
Edoxaban Concentration 
at trough (ng/mL) HDER No DR (60mg) 29.4[15.3-53.1] 36.1[20.0-63.8] 42.6[25.4-68.4] 
HDER DR (30mg) 18.2[10.0-38.8] 25.1[13.0-41.4] 28.8[16.5-45.8] 
LDER No DR (30mg) 14.0[7.3-27.3] 18.5[10.6-31.7] 22.8[13.4-36.0] 
LDER DR (15mg) 8.2[3.6-14.3] 11.6[6.6-19.6] 13.5[8.4-22.2] 
Anti FXa Activity at 
trough (IU/mL) HDER No DR (60mg) 0.5[0.3-1.0] 0.7[0.4-1.1] 0.8[0.5-1.3] 
HDER DR (30mg) 0.5[0.2-1.0] 0.5[0.3-0.9] 0.5[0.3-0.8] 
LDER No DR (30mg) 0.3[0.2-0.5] 0.4[0.2-0.5] 0.4[0.3-0.7] 
LDER DR (15mg) 0.2[0.2-0.3] 0.3[0.2-0.5] 0.3[0.2-0.5] 
DR; dose reduction, HDER; higher dose edoxaban regimen, LDER; lower dose edoxaban regimen. 
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Supplementary Table S2. Primary Outcomes by Dose Reduction (Higher dose edoxaban regimen (60/30 mg) 
  Event Rates (%/pt-yrs) Higher dose edoxaban regimen vs. warfarin 
Outcomes Age 
Did not meet edoxaban 
dose reduction criteria* 
Met edoxaban dose 
reduction criteria* 
Did not meet edoxaban 
dose reduction criteria* 
Met edoxaban dose 
reduction criteria* 
 
 3 way
Edox 60mg Warfarin Edox 30mg Warfarin HR [95% CI] HR [95% CI] Pint† Pint‡ 
Stroke or 
SEE 
<65 years 1.1 1.1 1.0 1.7 0.99 [0.67-1.47] 0.62 [0.20-1.90] 0.43 0.52 
65-74 years 1.4 1.6 2.6 2.5 0.85 [0.62-1.16] 1.01 [0.59-1.70] 0.60   
≥75 years 1.6 1.9 2.4 2.9 0.82 [0.60-1.12] 0.84 [0.61-1.15] 0.91   
Major 
Bleeding 
<65 years 1.4 1.8 1.9 1.9 0.79 [0.56-1.11] 1.04 [0.39-2.76] 0.62 0.09 
65-74 years 2.4 3.3 2.7 3.5 0.75 [0.58-0.96] 0.76 [0.45-1.30] 0.95   
≥75 years 4.4 4.1 3.4 6.0 1.06 [0.84-1.33] 0.58 [0.43-0.77] 0.0013   
 
*In the higher-dose edoxaban regimen, patients with moderate renal dysfunction, weight < 60 mg, or use of strong P-gp inhibitors received 
30 mg instead of 60 mg edoxaban once daily. There was no “dose reduction” for warfarin; instead the dose of warfarin was titrated to a 
target INR of 2.0-3.0. 
†p-interaction for dose reduction and treatment effect 
‡3 way p-interaction for dose reduction, treatment effect and age 
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Supplementary Table S3. Primary Outcomes by Dose Reduction (Lower dose edoxaban regimen 30/15 mg) 
  Event Rates (%/pt-yrs) Lower dose edoxaban regimen vs. warfarin 
Outcomes Age 
Did not meet edoxaban 
dose reduction criteria* 
Met edoxaban dose 
reduction criteria* 
Did not meet edoxaban 
dose reduction criteria* 
Met edoxaban dose 
reduction criteria*  3 way 
Edox 30mg Warfarin Edox 15 mg Warfarin HR [95% CI] HR [95% CI] Pint* Pint** 
 
Stroke or 
SEE 
<65 years 1.5 1.1 2.3 1.7 1.43 [0.99-2.08] 1.34 [0.55-3.29] 0.89 0.82 
65-74 years 1.6 1.6 3.0 2.5 0.94 [0.70-1.28] 1.16 [0.70-1.93] 0.49   
≥75 years 2.0 1.9 3.3 2.9 1.07 [0.80-1.45] 1.15 [0.86-1.54] 0.74   
 
Major 
Bleeding 
<65 years 0.8 1.8 0.5 1.9 0.43 [0.28-0.65] 0.24 [0.05-1.13] 0.48 0.05 
65-74 years 1.6 3.3 1.8 3.5 0.48 [0.36-0.63] 0.51 [0.29-0.93] 0.82  
≥75 years 2.7 4.1 1.6 6.0 0.65 [0.51-0.84] 0.27 [0.18-0.39] 0.0001   
 
*In the lower-dose edoxaban regimen, patients with moderate renal dysfunction, weight < 60 mg, or use of strong P-gp inhibitors received 
15 mg instead of 30 mg edoxaban once daily. There was no “dose reduction” for warfarin; instead the dose of warfarin was titrated to a 
target INR of 2.0-3.0. 
†p-interaction for dose reduction and treatment effect 
‡3 way p-interaction for dose reduction, treatment effect and age 
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Supplementary Table S4 Patient Characteristics in Very Elderly Population (≥ 80 years)                       
 
 
*See Figure 1 Legend for abbreviations and for data presentation. 
p value <0.001 for all comparisons except for hypertension (p=0.003), dyslipidemia (p=0.158), prior PCI (p=0.016), prior 
stroke or TIA (p=0.014), Type of AF (p=0.996), Time in therapeutic range (p=0.225), prior VKA experience (p=0.062), 
aspirin use (p=0.455), and thienopyridine use (p=0.174).   
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Supplementary Table S5 Patient Characteristics in Very Elderly Population (≥85 years) 
.  
p value <0.001 for all comparisons except for hypertension (p=0.044), dyslipidemia (p=0.172), prior PCI (p=0.962), prior 
stroke or TIA (p=0.864), Type of AF (p=0.630), time in therapeutic range (p=0.238), prior VKA experience (p=0.946), 
aspirin use (p=0.725), and thienopyridine use (p=0.233).. 
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Supplementary Table S6 Outcomes in Very Elderly Population (≥ 80 years)                                           
 
HDER; Higher dose edoxaban regimen, LDER; lower dose edoxaban 
*See Table 1 for abbreviations.  
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Supplementary Table S7 Outcomes Very Elderly Population (≥ 85 years) 
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Supplementary Table S8 Outcomes by patients aged <75 and ≥75 years 
 
 
HDER; Higher dose edoxaban regimen, LDER; lower dose edoxaban 
*See Table 1 for abbreviations.  
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Supplementary Figure S1. Age distribution 
The median age was 72 years (interquartile range, 64 to 78). 40.2% were aged ≥75 years including 899 (4.3%) in 
age group ≥85 years 
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Supplementary Figure S2. Efficacy and Safety Outcomes Comparing the Lower Dose Edoxaban Regimen 
vs. Warfarin by Age 
In the elderly, the risks of ISTH major bleeding (HR 0.47 [0.38-0.58]) and ICH (HR 0.30 [0.19-0.49]) were 
significantly reduced with the lower dose edoxaban regimen as compared to warfarin.  
See Figure 1 and 3 for abbreviations. 
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